Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Building and characterizing antibody-targeted lipidic nanotherapeutics.

Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC.

Methods Enzymol. 2012;502:139-66. doi: 10.1016/B978-0-12-416039-2.00007-0.

PMID:
22208985
2.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
3.

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.

J Control Release. 2001 Jul 6;74(1-3):95-113.

PMID:
11489487
4.

Targetability of novel immunoliposomes prepared by a new antibody conjugation technique.

Bendas G, Krause A, Bakowsky U, Vogel J, Rothe U.

Int J Pharm. 1999 Apr 20;181(1):79-93.

PMID:
10370205
5.

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.

Clin Cancer Res. 2002 Apr;8(4):1172-81.

6.

Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes.

Rothdiener M, Beuttler J, Messerschmidt SK, Kontermann RE.

Methods Mol Biol. 2010;624:295-308. doi: 10.1007/978-1-60761-609-2_20.

PMID:
20217604
7.

Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor.

Manjappa AS, Chaudhari KR, Venkataraju MP, Dantuluri P, Nanda B, Sidda C, Sawant KK, Murthy RS.

J Control Release. 2011 Feb 28;150(1):2-22. doi: 10.1016/j.jconrel.2010.11.002. Epub 2010 Nov 21. Review.

PMID:
21095210
8.

Targeted drugs and nanomedicine: present and future.

Debbage P.

Curr Pharm Des. 2009;15(2):153-72. Review.

PMID:
19149610
9.

Targeted drug delivery using immunoconjugates: principles and applications.

Pasquetto MV, Vecchia L, Covini D, Digilio R, Scotti C.

J Immunother. 2011 Nov-Dec;34(9):611-28. doi: 10.1097/CJI.0b013e318234ecf5. Review.

PMID:
21989410
10.

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW.

Cancer Res. 2006 Jul 1;66(13):6732-40.

11.

Tumor-directed targeting of liposomes.

Park YS.

Biosci Rep. 2002 Apr;22(2):267-81. Review.

PMID:
12428904
12.

pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.

Simard P, Leroux JC.

Int J Pharm. 2009 Nov 3;381(2):86-96. doi: 10.1016/j.ijpharm.2009.05.013. Epub 2009 May 14.

PMID:
19446624
13.

Lymphoid tissue targeting of anti-HIV drugs using liposomes.

Désormeaux A, Bergeron MG.

Methods Enzymol. 2005;391:330-51.

PMID:
15721390
14.

Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes.

Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y.

Pharm Res. 1996 Mar;13(3):352-9.

PMID:
8692725
15.

Pharmacokinetics and biodistribution of genetically-engineered antibodies.

Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK.

Q J Nucl Med. 1998 Dec;42(4):225-41. Review.

PMID:
9973838
16.

Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues.

Lyon RP, Meyer DL, Setter JR, Senter PD.

Methods Enzymol. 2012;502:123-38. doi: 10.1016/B978-0-12-416039-2.00006-9.

PMID:
22208984
17.

Immunoliposomes for cancer therapy.

Kontermann RE.

Curr Opin Mol Ther. 2006 Feb;8(1):39-45. Review.

PMID:
16506524
18.

Brain drug delivery of small molecules using immunoliposomes.

Huwyler J, Wu D, Pardridge WM.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14164-9.

19.

Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.

Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, Yasuda J, Obata K, Kikuchi H, Ishida T, Kiwada H, Harashima H.

Int J Pharm. 2007 Sep 5;342(1-2):194-200. Epub 2007 May 10.

PMID:
17583453
20.

Targeted SAINT-O-Somes for improved intracellular delivery of siRNA and cytotoxic drugs into endothelial cells.

Adrian JE, Morselt HW, Süss R, Barnert S, Kok JW, Asgeirsdóttir SA, Ruiters MH, Molema G, Kamps JA.

J Control Release. 2010 Jun 15;144(3):341-9. doi: 10.1016/j.jconrel.2010.03.003. Epub 2010 Mar 11.

PMID:
20226822

Supplemental Content

Support Center